A new type of meeting offering more detailed mid-assessment advice from the US Food and Drug Administration about generic drug applications will cost applications more valuable time.
GDUFA III: Convening Enhanced Mid-Cycle Meeting Will Cost Sponsors
Requesting the new meeting type for an ANDA assessment will trigger a goal date extension with another possible should an unsolicited application amendment also be necessary.
